Business ❯ Finance ❯ Stock Market

Pharmaceutical Stocks

Novo Nordisk Eli Lilly Pfizer Market Reactions Moderna Tariffs Market Performance AstraZeneca Eli Lilly and Company Vertex Pharmaceuticals Moderna, Inc. Pfizer Inc. Vaccine Manufacturers Sun Pharma Hims & Hers Kodiak Sciences Amgen Recursion Pharmaceuticals Viking Therapeutics Vanda Pharmaceuticals Bristol Myers Squibb Regeneron Pharmaceuticals Investor Reactions Ionis Pharmaceuticals Capricor Therapeutics Eli Lilly (LLY) Sangamo Therapeutics Zevra Therapeutics Emcure Pharmaceuticals COVID Vaccine Manufacturers Rocket Pharmaceuticals Company Performance Sudarshan Pharma Industries Ltd Hims & Hers Health Market Trends Vaccine Makers Competitor Analysis GSK and Spero Therapeutics Stock Activity Sudarshan Pharma Industries Sun Pharmaceutical Ltd. Drug Pricing Policies European Drugmakers Dr. Reddys Laboratories Biotech Stocks SPARC Shares Dr. Reddy's Laboratories Investment Trends Sarepta Therapeutics Indian Pharma Stocks Sigachi Industries Relmada Therapeutics Amylyx Pharmaceuticals Dr Reddy's Laboratories Jubilant Pharmova Xenon Pharmaceuticals Eli Lilly and Co. Cipla Piramal Pharma Market Impact AbbVie COVID-19 Vaccine Makers Eli Lilly and Novo Nordisk Wockhardt Ltd. Dr Reddy's Lab Gilead Sciences Lupin Pharmaceuticals Eli Lilly & Company Mira Pharmaceuticals Praxis Precision Medicines, Inc. Novo Nordisk and Eli Lilly Omeros Teva Pharmaceutical Sanofi SA Jazz Pharmaceuticals Investment Redcare Pharmacy Genmab Stock Sanofi Novartis AG Laurus Labs Ultragenyx Pharmaceutical Corvus Pharmaceuticals Bristol-Myers Squibb Company Merck & Co. Merck Arrowhead Pharmaceuticals Clearmind (CMND) Kodiak Sciences Stock BullFrog AI BullFrog AI Holdings AIM ImmunoTech ImmunityBio Investor Activity Acquisitions uniQure (QURE) Cohance Lifesciences Analyst Ratings Inhibrx Biosciences Definium Therapeutics Novartis

Court Rules Liquidia’s Yutrepia Infringes United Therapeutics Patent

A Delaware decision sets a near‑term remedies timetable that could narrow Yutrepia’s approved PH‑ILD use.

Kodiak Drugs Clear Phase 3 for Wet AMD and Shares Soar

Viking’s VK2735 Shows Durable Weight Loss With Less‑Frequent Dosing

Wall Street Lifts Eli Lilly After $1,600 Price Target Drives Rally

Novartis' Pelacarsen Fails Phase 3 After Lowering Lp(a)

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

Novartis Moves to File Oral MS Drug After Phase‑3 Win as Separate CAR‑T Trials Are Paused

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

Moderna and Merck Say Phase 3 Personalized mRNA Melanoma Vaccine Met Key Endpoints

Amylyx’s Avexitide Cuts Moderate‑to‑Severe Post‑Bariatric Hypoglycemia Events 55% in Phase 3

EyePoint Stock Collapses After Duravyu Misses Phase 3 Primary Endpoint

Capricor Seeks New FDA Path for Duchenne Drug After 9–3 Advisory Vote

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Eli Lilly Trades at a High Multiple as GLP‑1 Catalysts Loom

FDA Staff Flags Major Flaws in Capricor’s Deramiocel Data

UK Clears Oral Wegovy and Foundation Pledges Europe Research Cash

Definium’s Oral LSD Pill Meets Primary Endpoint in Phase 3 Depression Trial

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

FDA Agrees Three‑Year Phase I/II Data Can Support uniQure’s AMT‑130 Accelerated BLA

Moderna Restructures Leadership as It Prepares for Multiple Vaccine Launches